Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04435483 · ClinicalTrials.gov registry record · Phase 1
A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT04435483 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 39 participants.
The verdict
NCT04435483, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study is being conducted to support the clinical development of acalabrutinib in patients who are unable to swallow capsule and require nasogastric (NG) tube placement.
Interventions
- DRUG Acalabrutinib Treatment A
- DRUG Acalabrutinib Treatment B
- DRUG Acalabrutinib Treatment C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2020-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04435483
The ClinicalTrials.gov registry entry for NCT04435483 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Acalabrutinib Treatment A is the first listed.
NCT04435483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04435483 about?
NCT04435483 is a clinical study titled "A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers". This study is being conducted to support the clinical development of acalabrutinib in patients who are unable to swallow capsule and require nasogastric (NG) tube placement.
What is the current status of trial NCT04435483?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2020-05-22. Estimated completion is 2020-06-26.
What interventions are being tested in trial NCT04435483?
The interventions under investigation include: Acalabrutinib Treatment A (DRUG), Acalabrutinib Treatment B (DRUG), Acalabrutinib Treatment C (DRUG).
Who is sponsoring clinical trial NCT04435483?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.